{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:11:59Z","timestamp":1761984719585,"version":"build-2065373602"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T00:00:00Z","timestamp":1424217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s00535-015-1052-5","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T12:20:05Z","timestamp":1424175605000},"page":"1047-1053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan"],"prefix":"10.1007","volume":"50","author":[{"given":"Isao","family":"Sakaida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiwamu","family":"Okita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Tachikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetsugu","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,18]]},"reference":[{"key":"1052_CR1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3748\/wjg.v17.i10.1237","volume":"17","author":"E Biecker","year":"2011","unstructured":"Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol. 2011;17:1237\u201348.","journal-title":"World J Gastroenterol"},{"key":"1052_CR2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","volume":"9","author":"V Hasselblad","year":"2007","unstructured":"Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064\u20139.","journal-title":"Eur J Heart Fail"},{"key":"1052_CR3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10741-011-9248-0","volume":"17","author":"MR Costanzo","year":"2012","unstructured":"Costanzo MR, Jessup M. Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis. Heart Fail Rev. 2012;17:313\u201324.","journal-title":"Heart Fail Rev"},{"key":"1052_CR4","author":"K Madan","year":"2011","unstructured":"Madan K, Mehta A. Management of renal failure and ascites in patients with cirrhosis. Int J Hepatol. 2011. doi: 10.4061\/2011\/790232 .","journal-title":"Int J Hepatol"},{"key":"1052_CR5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jcrc.2013.10.004","volume":"29","author":"GD Kitsios","year":"2014","unstructured":"Kitsios GD, Mascari P, Ettunsi R, et al. Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. J Crit Care. 2014;29:253\u20139.","journal-title":"J Crit Care"},{"issue":"Suppl 3","key":"1052_CR6","first-page":"S193","volume":"7","author":"D Barchel","year":"2012","unstructured":"Barchel D, Almoznino-Sarafian D, Shteinshnaider M, et al. Hypoalbuminemia. Intern Emerg Med. 2012;7(Suppl 3):S193\u20139.","journal-title":"Intern Emerg Med"},{"key":"1052_CR7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ki.1986.83","volume":"29","author":"P Fauchald","year":"1986","unstructured":"Fauchald P. Transcapillary colloid osmotic gradient and body fluid volumes in renal failure. Kidney Int. 1986;29:895\u2013900.","journal-title":"Kidney Int"},{"key":"1052_CR8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/bja\/85.4.599","volume":"85","author":"JP Nicholson","year":"2000","unstructured":"Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85:599\u2013610.","journal-title":"Br J Anaesth"},{"key":"1052_CR9","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/ajhp\/60.13.1330","volume":"60","author":"M Tanzi","year":"2003","unstructured":"Tanzi M, Gardner M, Megellas M, et al. Evaluation of the appropriate use of albumin in adult and pediatric patients. Am J Health Syst Pharm. 2003;60:1330\u20135.","journal-title":"Am J Health Syst Pharm"},{"key":"1052_CR10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00535-010-0282-9","volume":"46","author":"Y Narahara","year":"2011","unstructured":"Narahara Y, Kanazawa H, Fukuda T, et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol. 2011;46:78\u201385.","journal-title":"J Gastroenterol"},{"key":"1052_CR11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"1052_CR12","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1177\/030006051204000637","volume":"40","author":"I Sakaida","year":"2012","unstructured":"Sakaida I, Yanase M, Kobayashi Y, et al. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. J Int Med Res. 2012;40:2381\u201393.","journal-title":"J Int Med Res"},{"key":"1052_CR13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/0300060513480089","volume":"41","author":"I Sakaida","year":"2013","unstructured":"Sakaida I, Yamashita S, Kobayashi T, et al. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. J Int Med Res. 2013;41:835\u201347.","journal-title":"J Int Med Res"},{"key":"1052_CR14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hepr.12099","volume":"44","author":"K Okita","year":"2014","unstructured":"Okita K, Kawazoe S, Hasebe C, et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:83\u201391.","journal-title":"Hepatol Res."},{"key":"1052_CR15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","volume":"44","author":"I Sakaida","year":"2014","unstructured":"Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73\u201382.","journal-title":"Hepatol Res"},{"key":"1052_CR16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/hepr.12171","volume":"44","author":"I Sakaida","year":"2014","unstructured":"Sakaida I, Okita K. Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy. Hepatol Res. 2014;44:735\u20139.","journal-title":"Hepatol Res."},{"key":"1052_CR17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00535-008-2178-5","volume":"43","author":"A Kasahara","year":"2008","unstructured":"Kasahara A, Kita K, Tomita E, et al. Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis: a multicenter clinical study. J Gastroenterol. 2008;43:464\u201372.","journal-title":"J Gastroenterol"},{"key":"1052_CR18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","volume":"38","author":"KP Moore","year":"2003","unstructured":"Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258\u201366.","journal-title":"Hepatology"},{"key":"1052_CR19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2471\/BLT.08.050955","volume":"86","author":"JR Williams","year":"2008","unstructured":"Williams JR. The declaration of helsinki and public health. Bull World Health Organ. 2008;86:650\u20132.","journal-title":"Bull World Health Organ"},{"key":"1052_CR20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/dewb.12004","volume":"14","author":"S Kaur","year":"2014","unstructured":"Kaur S, Choy CY. Ethical considerations in clinical trials: a critique of the ICH-GCP guideline. Dev World Bioeth. 2014;14:20\u20138.","journal-title":"Dev World Bioeth"},{"key":"1052_CR21","author":"B Phakdeekitcharoen","year":"2012","unstructured":"Phakdeekitcharoen B, Boonyawat K. The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study. BMC Nephrol. 2012. doi: 10.1186\/1471-2369-13-92 .","journal-title":"BMC Nephrol"},{"key":"1052_CR22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00467-008-1062-0","volume":"24","author":"R Dharmaraj","year":"2009","unstructured":"Dharmaraj R, Hari P, Bagga A. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. Pediatr Nephrol. 2009;24:775\u201382.","journal-title":"Pediatr Nephrol"},{"key":"1052_CR23","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1111\/j.1572-0241.2005.00271.x","volume":"100","author":"JM P\u00e9ron","year":"2005","unstructured":"P\u00e9ron JM, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol. 2005;100:2702\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1052_CR24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3346\/jkms.2001.16.4.448","volume":"16","author":"KY Na","year":"2001","unstructured":"Na KY, Han JS, Kim YS, et al. Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? J Korean Med Sci. 2001;16:448\u201354.","journal-title":"J Korean Med Sci"},{"key":"1052_CR25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ki.1987.192","volume":"32","author":"M Inoue","year":"1987","unstructured":"Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int. 1987;32:198\u2013203.","journal-title":"Kidney Int"},{"key":"1052_CR26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0168-8278(99)80194-9","volume":"30","author":"P Gentilini","year":"1999","unstructured":"Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol. 1999;30:639\u201345.","journal-title":"J Hepatol"},{"key":"1052_CR27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJM199808063390607","volume":"339","author":"DC Brater","year":"1998","unstructured":"Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387\u201395.","journal-title":"N Engl J Med"},{"key":"1052_CR28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7326\/0003-4819-102-2-164","volume":"102","author":"RJ Anderson","year":"1985","unstructured":"Anderson RJ, Chung HM, Kluge R, et al. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med. 1985;102:164\u20138.","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"1052_CR29","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s10557-011-6357-x","volume":"25","author":"M Furukawa","year":"2011","unstructured":"Furukawa M, Umehara K, Kashiyama E. Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S83\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl 1","key":"1052_CR30","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s10557-011-6298-4","volume":"25","author":"M Hori","year":"2011","unstructured":"Hori M. Tolvaptan for heart failure patients with volume overload. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S1\u20134.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1052_CR31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1253\/circj.CJ-66-0093","volume":"78","author":"K Kinugawa","year":"2014","unstructured":"Kinugawa K, Sato N, Inomata T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J. 2014;78:844\u201352.","journal-title":"Circ J"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1052-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-015-1052-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1052-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:08:14Z","timestamp":1747660094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-015-1052-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,18]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1007\/s00535-015-1052-5","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2015,2,18]]}}}